Fundraising FoxMuReva
Brecksville, US · Founded 2018 · 3 known investors
Find your way into MuReva
Sign up to see every warm intro you have to MuReva
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MuReva team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MuReva Phototherapy develops oral phototherapy devices intended to reduce dose-limiting side effects, such as oral mucositis, in cancer patients undergoing radiation and chemotherapy. Spun off from fiber-optic lighting company Lumitex, its light-transmission technology is being evaluated in a U.S. multicenter clinical trial and is not yet commercially available.
Founders & leadership
VK
Vedang KothariPresident
SS
Sam ShelnuttVice-President of EngineeringSam Shelnutt is Vice-President of Engineering at MuReva Phototherapy, an oral phototherapy device company spun from Lumitex. He has extensive experience leading engineering teams in medical device development, with expertise in quality management systems, FDA regulatory compliance (CFR Part 820), and ISO standards (13485, 14971).
MM
Michael MarottaVice President of Clinical AffairsVice President of Clinical Affairs at MuReva Phototherapy, which develops oral phototherapy devices to reduce side effects in cancer patients undergoing radiation and chemotherapy. His background includes experience in clinical research compliance, working with sponsoring companies, contract research organizations, and investigators across device, biologic, and pharmaceutical research.
PB
Peter BroerNamed on SEC filing
CM
Creighton MurchNamed on SEC filing
AR
Austin RuhleChief Financial Officer
Investors · 3
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2018
▶$1.3MraisedDec 2018 · 18 investors · ManufacturingRule 506(b)
▶$1.3MraisedDec 2018 · 18 investors · Manufacturing
Rule 506(b)Officers, directors & promoters on the filing
- Peter BroerDirector
- Vedang Phototherapy KothariExecutive Officer
- Creighton MurchDirector
- Austin RuhleExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does MuReva do?
- MuReva Phototherapy develops oral phototherapy devices intended to reduce dose-limiting side effects, such as oral mucositis, in cancer patients undergoing radiation and chemotherapy. Spun off from fiber-optic lighting company Lumitex, its light-transmission technology is being evaluated in a U.S. multicenter clinical trial and is not yet commercially available.
- Who are MuReva's investors?
- MuReva's investors include Angel Physicians Fund, Band of Angels, Jumpstart Ventures.
- How much funding has MuReva raised?
- MuReva has disclosed $1.3M raised across 1 round.
- Where is MuReva headquartered?
- MuReva is headquartered in Brecksville, US.